The Impact of Sulfonylureas on Tacrolimus Apparent Clearance Revealed by a Population Pharmacokinetics Analysis in Chinese Adult Liver-Transplant Patients

Abstract

Concurrent therapy with sulfonylureas influenced tacrolimus CL/F in liver transplantation patients. These results and model will help clinicians to optimize tacrolimus regimens in Chinese liver transplantation patients.

Donor IL-18 Rs5744247 Polymorphism as a New Biomarker of Tacrolimus Elimination in Chinese Liver Transplant Patients During the Early Post-Transplantation Period: Results from Two Cohort Studies

“…Our result that total bilirubin affected tacrolimus clearance was consistent with previous studies that the pharmaco kinetics of tacrolimus was influenced by the total bilirubin level (TBIL) and total plasma proteins [15][16][17]. In multivariate analysis, besides Donor IL-18 rs5744247 polymorphism as a new biomarker of tacrolimus elimination Research Article the obvious factor daily dose total bilirubin together with donor CYP3A5 and IL-18 gene polymorphisms were identified as independent influence factor of tacroliums C/D ratio.…”

“…Several studies have confirmed that liver function affects the pharmacokinetics of tacrolimus [15][16][17]. Hepatocytes from liver grafts following liver transplantation that are thought to be lost due to ischemia-reperfusion injury and alloimmune response need to be replaced.…”

Population pharmacokinetics of tacrolimus in paediatric systemic lupus erythematosus based on real-world study

“…[6][7][8][9][10][11][12][13][14][15] However, tacrolimus has a narrow therapeutic window and displays considerable interindividual and intra-individual variabilities in its pharmacokinetics, with poor correlation between drug dosage and blood concentrations, making it difficult to define an optimal dose schedule. 18 Currently, different tacrolimus PPK models have been set up for various populations including renal transplant patients, [19][20][21][22][23][24] liver transplant patients, [25][26][27][28][29][30] haematopoietic stem cell transplant patients 31 and lung transplant patients. Moreover, the population analysis methodology differentiates between interindividual variability and residual unexplained variability.…”

Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in Chinese liver transplant patients

“…MAP has the following advantages: patient characteristics can be incorporated into the model to improve the prediction of individualized AUC; the predictive performance can be improved with additional data; the sampling time can be chosen flexibly; and different PK parameters can be predicted simultaneously. Different TAC PPK models have been established in various populations including renal transplant patients, liver transplant patients, hematopoietic stem cell transplant patients and lung transplant patients . Some studies have tried to estimate TAC AUC using MAP.…”

“…Some studies have tried to estimate TAC AUC using MAP. Some other TAC PPK studies focused on Chinese liver transplant patients . However, they only used conventional TDM data for modelling and assaying the individualized PPK parameters assay rather through Bayesian estimation.…”